Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid
- Development stage
- Phase 2
- Lead developer
- Baxter
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination is used in the treatment of HER2-positive breast cancer. **Cyclophosphamide** and **doxorubicin** are chemotherapeutic agents that work by interfering with DNA replication and function. **Docetaxel** is a taxane that inhibits cell division. **Trastuzumab** is a monoclonal antibody targeting the HER2 receptor, used in HER2-positive cancers. **Zoledronic acid** is a bisphosphonate that inhibits bone resorption and is used to prevent skeletal-related events in cancer patients. The combination enhances anti-tumor activity and may improve outcomes in breast cancer by synergizing with chemotherapy and anti-HER2 therapy.
- Other names
- zoledronic acid + doxorubicin + cyclophosphamide + docetaxel + trastuzumabZoledronic Acid Neoadjuvant in HER2+ Breast Cancer
02
Targets
DNAFDPS (Farnesyl pyrophosphate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + trastuzumab + zoledronic acid.